Evidence map›Paper›PMID 25808939›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2015

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Lynn M Bekris, Debby W Tsuang, Elaine R Peskind, Chang E Yu, Thomas J Montine, Jing Zhang, Cyrus P Zabetian, James B Leverenz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Episodic recognition memory and the hippocampus in Parkinson's disease: A review.Cortex; a journal devoted to the study of the nervous system and behavior · 2019
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Lynn M BekrisGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Debby W TsuangNorthwest Network Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
Elaine R PeskindNorthwest Network Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
Chang E YuGeriatric Research, Education, and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
Thomas J MontineNorthwest Network Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
Jing ZhangNorthwest Network Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
Cyrus P ZabetianGeriatric Research, Education, and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, Washington, USA.
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Mental Illness Research, Education and Clinical Centers · USVA Northwest Network · USCleveland Clinic · USLou Ruvo Brain Institute · USVA Puget Sound Health Care System · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI WIJSMAN, ELLEN M · 1985 to 2019
$57.2M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Biomarker Expression and Regulatory Haplotypes in Alzheimer's DiseaseR00AG034214 · NIA · UNIVERSITY OF WASHINGTON · PI BEKRIS, LYNN · 2012 to 2014
$725k
Biomarker Expression and Regulatory Haplotypes in Alzheimer's DiseaseK99AG034214 · NIA · UNIVERSITY OF WASHINGTON · PI BEKRIS, LYNN · 2010 to 2011
$254k
NIA NIH HHS 4R00AG034214NIA NIH HHS K99 AG034214NIA NIH HHS K99AG034214NIA NIH HHS P50 AG005136NIA NIH HHS P50AG005136NIA NIH HHS R00 AG034214NINDS NIH HHS P50 NS062684NINDS NIH HHS P50NS062684PHS HHS P50-AB005136
6 · The paper itself

Abstract

backgroundOf recent interest is the finding that certain cerebrospinal fluid (CSF) biomarkers traditionally linked to Alzheimer's disease (AD), specifically amyloid beta protein (Aβ), are abnormal in PD CSF. The aim of this exploratory investigation was to determine whether genetic variation within the amyloid precursor protein (APP) processing pathway genes correlates with CSF Aβ42 levels in Parkinson's disease (PD).

methodsParkinson's disease (n = 86) and control (n = 161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP. The SNP genotypes were tested for their association with CSF biomarkers and PD risk while adjusting for age, sex, and APOE ɛ4 status.

resultsSignificant correlation with CSF Aβ42 levels in PD was observed for two SNPs, (APP rs466448 and APH1B rs2068143). Conversely, significant correlation with CSF Aβ42 levels in controls was observed for three SNPs (APP rs214484, rs2040273, and PSEN1 rs362344).

conclusionsIn addition, results of this exploratory investigation suggest that an APP SNP and an APH1B SNP are marginally associated with PD CSF Aβ42 levels in APOE ɛ4 noncarriers. Further hypotheses generated include that decreased CSF Aβ42 levels are in part driven by genetic variation in APP processing genes. Additional investigation into the relationship between these findings and clinical characteristics of PD, including cognitive impairment, compared with other neurodegenerative diseases, such as AD, are warranted. © 2015 International Parkinson and Movement Disorder Society.

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesApolipoprotein E4BiomarkersFemaleHumansMaleMiddle AgedParkinson DiseasePeptide FragmentsPolymorphism, Single NucleotideAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesApolipoprotein E4BiomarkersPeptide FragmentsADAM10APH1BAPPBACE1BACE2cerebrospinal fluidNCSTNParkinson's diseasePEN2PSEN1PSEN2

Identifiers

PMID25808939
PMCPMC4478197
OpenAlexW2121054334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.